The in vitro and in vivo studies described above, revealing that SHIP2 overexpression suppresses insulin signalling and debilitates glucose metabolism, have increased the interest to develop SHIP2 inhibitors as a potential therapeutic approach to treat obesity‐induced insulin resistance and T2D. The gene discussed is INPPL1; the disease is obesity due to melanocortin 4 receptor deficiency.